This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nazratun, N Articles by Tan, S Y Search for Related Content PubMed PubMed Citation Articles by Nazratun, N Articles by Tan, S Y Social Bookmarking                   What's this?

Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients

A A Mahmood

Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

U R Kuppusamy

Department of Molecular Medicine, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia. Tel: +60 3 79674900; Fax: +60 3 79676600; umah{at}um.edu.my

T Sara Ahmad

Department of Orthopaedic Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

S Y Tan

Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

The excess accumulation of advanced glycation end products (AGEs) contributes to the chronic complications of type 2 diabetes mellitus (DM) and renal failure. Biopsy specimens (n = 184) of arterial (n = 92) and venous (n = 92) tissues were obtained (radial artery and cephalic vein) from end-stage renal disease (ESRD) patients with or without DM and normal healthy subjects (n = 12) requiring surgery (trauma patients). Immunohistochemical assessment of the blood vessels revealed the presence of pentosidine (AGE marker) in both veins and arteries in 72% of the ESRD patients. The percentage of arteries and veins that showed positive pentosidine staining in ESRD patients with type 2 DM alone was 100% and 92% respectively, in the non-diabetic ESRD patients it was <70% (for arteries and veins), and in the ESRD patients with hypertension as an additional co-morbidity to type 2 DM it was 70% and 82%, respectively. The veins of ESRD patients with DM showed a strong (+++) positive staining and very strong (++++) positive staining was observed in the patients with DM and hypertension. Only mild (+) or moderate (++) pentosidine staining intensity was observed in the arteries of ESRD patients without or with comorbidities, respectively. The accumulation of AGE in the vein rather than the artery may be a better reflection of the extent of complications of ESRD.

Key Words: AGE • artery • diabetes mellitus • ESRD • pentosidine • vein

References

• Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997; 12: 255–258.[Abstract/Free Full Text]
• Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549–1557.[Abstract/Free Full Text]
• Takaeuchi M, Yanase Y, Matsuura N et al. Immunological detection of a novel advanced glycation end-product. Mol Med 2001; 11: 783–791.
• Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buocristiani U. Daily hemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002; 17: 871–878.[Abstract/Free Full Text]
• Izuhara Y, Miyata T, Ueda Y et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant 1999; 14: 576–580.[Abstract/Free Full Text]
• Tsukahara H, Shibata R, Ohta N et al. High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress. Metabolism 2003; 52: 1601–1605.[CrossRef][ISI][Medline] [Order article via Infotrieve]
• Suliman ME, Heimburger O, Barany P et al. Plasma pentosidine is associated with inflammation and malnutrition in end stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14: 1614–1622.[Abstract/Free Full Text]
• Dawnay A. Renal clearance of glycation adducts: antiglycation defense in uremia and dialysis. Biochem Soc Trans2003; 31: 1386–1389.[ISI][Medline] [Order article via Infotrieve]
• Makita Z, Radoff S, Rayfield EJ et al. Advanced glycation endproducts in patients with diabetic nephropathy. N Eng J Med1991; 352: 836–842.
• Bucala R, Vlassara H. Advanced glycation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995; 26: 875–888.[ISI][Medline] [Order article via Infotrieve]
• Kuppusamy UR, Indran M, Tsara A, Wong SW, Tan SY, Mahmood AA. Comparison of oxidative damage in Malaysian end-stage renal disease patients with or without non-insulin dependent diabetes mellitus. Clin Chim Acta 2005; 351: 197–201.[CrossRef][ISI][Medline] [Order article via Infotrieve]
• Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Eng J Med 1988; 318: 1315–1321.[ISI][Medline] [Order article via Infotrieve]
• Stein G, Frank S, Mahiout A et al. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001; 16: 999–1008.[Abstract/Free Full Text]
• Miyata T, Kurokawa K, van Ypersele de Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000; 11: 1744–1752.[Free Full Text]
• Tokgoz H, Onaran M, Senocak C, Polat F, Sert S. Temporary vascular access via the external iliac vein as a salvage procedure: a report of two cases. J Vasc Access 2005; 6: 200–202.[Medline] [Order article via Infotrieve]
• Brophy DF, Martin RJ, Gehr TWB, Carr ME. A hypothesis generating study to evaluate platelet activity in diabetics with chronic kidney disease. Thromb J 2005; 3: 3–9.[CrossRef][Medline] [Order article via Infotrieve]
• Obrenovich ME, Monnier VM. Glycation stimulates amyloid formation. Sci Aging Knowledge Environ 2004; 2: pe3-pe3.
• Miyata T, Oda O, Inagi R et al. ß2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243–1252.[ISI][Medline] [Order article via Infotrieve]
• Beisswenger PJ, Moore LL, Brinck-Johnssen T, Churpey TJ. Increased collagen-linked pentosidine levels and advanced glycation end products in early diabetic nephropathy. J Clin Invest 1993; 92: 212–217.[ISI][Medline] [Order article via Infotrieve]
• Kislinger T, Fu C, Huber B et al. N-(Carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulated gene expression. J Biol Chem 1999; 274: 31–31 740–749.
• Yonekura H, Yamamoto Y, Sakurai S et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097–1109.[CrossRef][ISI][Medline] [Order article via Infotrieve]

CiteULike

Connotea

Del.icio.us

Digg

Reddit

Technorati

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nazratun, N Articles by Tan, S Y Search for Related Content PubMed PubMed Citation Articles by Nazratun, N Articles by Tan, S Y Social Bookmarking                   What's this?